The therapeutic approach was safe, but the study did not meet its primary efficacy outcome using the six-minute walking test.

Novo Nordisk announced results of the Phase IIIb STRIDE trial of semaglutide’s impact on walking capacity in people with PAD ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

At ACC 2025, new real-world safety data were presented on sotatercept, a novel fusion protein for pulmonary arterial ...

The trend of prescribing semaglutide to treat cardiovascular disease is expected to continue to grow. At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results were ...

The Lancet research papers build on the WHO’s Guidance for best practices in clinical trials released in September 2024.

Epicrispr has raised $68m in the initial close of its Series B financing round to commence the clinical trial of EPI-321 for ...

Lipocine has announced the commencement of a Phase III clinical trial of LPCN 1154, being developed for postpartum depression ...

Medidata has launched the Medidata Site Insights Program, aimed at expediting the delivery of life-changing therapy to trial ...

Biotech and biopharma companies have battled with a drought of private investment in recent years but could now face ...

While Cassava is stopping investigations into simufilam in Alzheimer’s disease, the therapy is now being evaluated in ...

Early results from Wave's ongoing DMD Phase II trial saw a decline in muscle necrosis and inflammation in the trial ...